Yusuke Nakamura to Pharmacogenetics
This is a "connection" page, showing publications Yusuke Nakamura has written about Pharmacogenetics.
Connection Strength
3.529
-
The era of immunogenomics/immunopharmacogenomics. J Hum Genet. 2018 Jul; 63(8):865-875.
Score: 0.487
-
The current and future applications of immunopharmacogenomics. Clin Adv Hematol Oncol. 2015 Dec; 13(12):815-7.
Score: 0.410
-
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet. 2013 Jun; 58(6):327-33.
Score: 0.343
-
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012 Sep 26; 4(153):153ps18.
Score: 0.329
-
Pharmacogenomics and drug toxicity. N Engl J Med. 2008 Aug 21; 359(8):856-8.
Score: 0.246
-
Japanese single nucleotide polymorphism database for 267 possible drug-related genes. Cancer Sci. 2006 Jan; 97(1):16-24.
Score: 0.206
-
[BioBank Japan project]. Nihon Rinsho. 2005 Dec; 63 Suppl 12:35-41.
Score: 0.205
-
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6.
Score: 0.182
-
[SNP collection, pharmacogenomics, and the future of drug therapy]. Gan To Kagaku Ryoho. 2002 Sep; 29(9):1665-73.
Score: 0.164
-
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends Pharmacol Sci. 2017 01; 38(1):15-24.
Score: 0.110
-
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016 Feb; 107(2):107-15.
Score: 0.104
-
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 01; 21(19):4337-46.
Score: 0.099
-
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 2013 Sep; 14(12):1383-7.
Score: 0.088
-
Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug; 104(8):1074-82.
Score: 0.086
-
New pharmacogenetic test for detecting an HLA-A*31: 01 allele using the InvaderPlus assay. Pharmacogenet Genomics. 2012 Jun; 22(6):441-6.
Score: 0.080
-
Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet. 2012; 27(1):122-31.
Score: 0.077
-
Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics. 2010 Sep; 20(9):565-8.
Score: 0.071
-
DNA variations in human and medical genetics: 25 years of my experience. J Hum Genet. 2009 Jan; 54(1):1-8.
Score: 0.064
-
Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet. 2006; 51(3):249-253.
Score: 0.052
-
Inference from the relationships between linkage disequilibrium and allele frequency distributions of 240 candidate SNPs in 109 drug-related genes in four Asian populations. J Hum Genet. 2004; 49(10):558-572.
Score: 0.047
-
Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. J Clin Oncol. 2019 08 01; 37(22):1982-1983.
Score: 0.033
-
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. 2012 Apr; 22(4):247-53.
Score: 0.020
-
Similarity of the allele frequency and linkage disequilibrium pattern of single nucleotide polymorphisms in drug-related gene loci between Thai and northern East Asian populations: implications for tagging SNP selection in Thais. J Hum Genet. 2006; 51(10):896-904.
Score: 0.014
-
A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms. J Hum Genet. 2005; 50(9):442-447.
Score: 0.013